Jun 10, 2021 - Health

Pharma industry insiders disavow FDA's approval of Aduhelm

Blue FDA logo on a white sign with the sky background.
Photo: Sarah Silbiger/Getty Images

A new poll of more than 1,400 people who work in the biotech and pharmaceutical industries by John Carroll of Endpoints News reveals a clear consensus: The FDA made a big mistake approving Aduhelm, Biogen's Alzheimer's treatment, and the $56,000 price tag does not match any possible benefit.

Why it matters: Even the industry's own experts are not defending the FDA and Biogen.

What they're saying: Many of the submitted comments are worth reading in full, but this one captured the general tenor of the responses Endpoints received:

  • "Aducanumab priced at $56k with the efficacy of a sugar pill is taking advantage of patients, the health care system and is ruthless," one commenter said.
Go deeper